IPA’s Subsidiary BioStrand Entered into a Research Collaboration and License Agreement with BriaCell to Discover and Develop Anti-Cancer Antibodies
Shots:
- BioStrand to receive an up front of $500,000 & will be eligible to receive future success-based development & clinical milestones along with royalties, following the successful Ab discovery. The companies collaborated on the design, discovery, and development of anti-cancer Abs
- The collaboration will utilize BioStrand’s LENSai software (developed from IPA’s HYFT Universal Fingerprint technologies) for in silico Ab discovery to develop clinical molecules
- The collaboration combines BioStrand’s revolutionary AI-powered technology & its cutting-edge protein engineering platform for the discovery of potent anti-cancer therapies & will complement BriaCell’s current immunotherapy pipeline for innovative anti-cancer therapies
Ref: Businesswire | Image: IPA
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
